Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Alexander

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Diabetes Care|October 28, 2003
The coming of age of the metabolic syndromeCharles M Alexander
Journal of the American College of Cardiology|March 21, 2020
Is Heart Failure Still the Frequent, Forgotten, and Often Fatal Complication of Diabetes?Charles M Alexander
Diabetes Care|June 26, 2014
Comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062Richard D Carr, Charles M Alexander
Clinics in Geriatric Medicine|June 27, 2020
Renal Evaluation and ProtectionRawan Amir, Sara Suhl, Charles M Alexander
The American Journal of Cardiology|September 26, 2006
Metabolic syndrome and hyperglycemia: congruence and divergenceCharles M Alexander, Pamela B Landsman, Scott M Grundy
Diabetes Care|November 25, 2003
Lowering the criterion for impaired fasting glucose will not provide clinical benefitMayer B Davidson, Pamela B Landsman, Charles M Alexander
Clinical Therapeutics|January 30, 2010
Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claimsColleen A McHorney, C Victor Spain, Charles M Alexander, et al.
Preventing Chronic Disease|June 17, 2006
Employer-paid nonmedical costs for patients with diabetes and end-stage renal diseaseSachin J Kamal-Bahl, Susan Pantely, Bruce Pyenson, et al.
Health and Quality of Life Outcomes|October 24, 2009
Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetesTom Stargardt, Linda Gonder-Frederick, Karl J Krobot, et al.
Journal of General Internal Medicine|December 23, 2003
Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physiciansKathleen A Foley, Joseph Vasey, Charles M Alexander, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Diabetes Care|October 28, 2003
The coming of age of the metabolic syndromeCharles M Alexander
Journal of the American College of Cardiology|March 21, 2020
Is Heart Failure Still the Frequent, Forgotten, and Often Fatal Complication of Diabetes?Charles M Alexander
Diabetes Care|June 26, 2014
Comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062Richard D Carr, Charles M Alexander
Clinics in Geriatric Medicine|June 27, 2020
Renal Evaluation and ProtectionRawan Amir, Sara Suhl, Charles M Alexander
The American Journal of Cardiology|September 26, 2006
Metabolic syndrome and hyperglycemia: congruence and divergenceCharles M Alexander, Pamela B Landsman, Scott M Grundy
Diabetes Care|November 25, 2003
Lowering the criterion for impaired fasting glucose will not provide clinical benefitMayer B Davidson, Pamela B Landsman, Charles M Alexander
Clinical Therapeutics|January 30, 2010
Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claimsColleen A McHorney, C Victor Spain, Charles M Alexander, et al.
Preventing Chronic Disease|June 17, 2006
Employer-paid nonmedical costs for patients with diabetes and end-stage renal diseaseSachin J Kamal-Bahl, Susan Pantely, Bruce Pyenson, et al.
Health and Quality of Life Outcomes|October 24, 2009
Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetesTom Stargardt, Linda Gonder-Frederick, Karl J Krobot, et al.
Journal of General Internal Medicine|December 23, 2003
Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physiciansKathleen A Foley, Joseph Vasey, Charles M Alexander, et al.
Pageof 5